Denise Myshko

One notable change: CVS Caremark has removed the Humira biosimilar Amjevita and now prefers Hyrimoz and an unbranded biosimilar.

Bimekizumab is the first dual IL-17 A/F inhibitor to treat moderate-to-severe plaque psoriasis. It launches with a list price of $7,200 per syringe.

Almost 80% of patients in an extension study maintained clear or almost clear skin, and 90% of patients saw continued improvements in itch.

Checkpoint inhibitors such as pembrolizumab nivolumab are playing a major role in cancer treatment, but they can also produce adverse events that affect the skin.